Description
SGC0946 is an inhibitor of the non-SET domain-containing methyltransferase DOT1L (IC50 = 0.3 nM).1 It is selective for DOT1L over a panel of 12 additional protein methyltransferases, DNA methyltransferase 1 (DNMT1), and a panel of 29 receptors and ion channels. SGC0946 reduces the levels of dimethylated lysine 79 on histone 3 (H3K79me2) in MCF-10A breast cancer cells (IC50 = 8.8 nM). It selectively reduces the viability of isolated human cord blood cells transformed with an MLL-AF9 fusion oncogene over those transformed with a TLS-ERG fusion oncogene when used at concentrations of 1 and 5 µM. Adoptive transfer of isolated human CD3+ T cells pre-incubated with SGC0946 (0.5 µM) prevents weight loss, increases survival, and reduces hepatic and colonic lymphocyte infiltration in a xenogeneic mouse model of graft versus host disease (GVHD).2WARNING This product is not for human or veterinary use.
References
[1] WENYU YU. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.[J]. Nature Communications, 2012: 1288. DOI:
10.1038/ncomms2304[2] YUKI KAGOYA. DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.[J]. Nature Communications, 2018: 1915. DOI:
10.1038/s41467-018-04262-0